Memorial Sloan Kettering DCN1-UBC12 Inhibitor Patent Granted
Summary
The USPTO granted US Patent 12605373B2 to Memorial Sloan Kettering Cancer Center on April 21, 2026. The patent covers substituted 1-phenyl-3-(piperidin-4-yl)urea analogs as inhibitors of DCN1-UBC12 interaction and DCN1-mediated cullin-RING ligase activity. The application (18596521) was filed March 5, 2024, with 14 claims allowed.
What changed
The USPTO issued US Patent 12605373B2 to Memorial Sloan Kettering Cancer Center on April 21, 2026. The patent protects substituted 1-phenyl-3-(piperidin-4-yl)urea analogs and related compounds as inhibitors of DCN1-UBC12 interaction and DCN1-mediated cullin-RING ligase activity, with applications including methods of treating disorders associated with these dysfunctions and methods of male contraception.
Affected parties in the pharmaceutical and oncology research sectors should be aware that this patent establishes intellectual property rights over a specific class of compounds and their therapeutic uses, which may affect freedom-to-operate analyses for competing drug development programs targeting similar pathways.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and compositions of inhibiting DCN1-UBC12 interaction
Grant US12605373B2 Kind: B2 Apr 21, 2026
Assignee
Memorial Sloan Kettering Cancer Center
Inventors
Jaeki Min, Daniel C. Scott, Deepak Bhasin, Brenda A. Schulman, Bhuvanesh Singh, Jared T. Hammill, R. Kiplin Guy
Abstract
In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
CPC Classifications
C07D 401/04 C07D 405/06 C07D 401/06 C07D 471/04 C07D 405/12 C07D 409/14 C07D 417/06 C07D 401/12 C07D 417/04 C07D 211/58 A61K 31/4545 A61K 31/451 A61K 31/454 A61K 31/17 A61K 31/506 A61K 31/4525 A61P 35/00
Filing Date
2024-03-05
Application No.
18596521
Claims
14
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.